Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Gadoxetate disodium, a modern hepatospecific MRI contrast agent: Indirect signs for gadolinium deposition in the brain structures with signal intensity increase after intravenous application

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F18%3A43917428" target="_blank" >RIV/00216208:11120/18:43917428 - isvavai.cz</a>

  • Nalezeny alternativní kódy

    RIV/68081740:_____/18:00497502 RIV/00216208:11130/18:10383596 RIV/00064173:_____/18:N0000141

  • Výsledek na webu

  • DOI - Digital Object Identifier

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Gadoxetate disodium, a modern hepatospecific MRI contrast agent: Indirect signs for gadolinium deposition in the brain structures with signal intensity increase after intravenous application

  • Popis výsledku v původním jazyce

    Background: Gadolinium brain deposits after intravenous application of gadolinium-based contrast agents (GBCA) have been recently reported. Aim: We focused selectively on gadoxetate disodium, a hepatospecific linear GBCA. There are currently only a few studies in peer-reviewed literature focused selectively on gadoxetate disodium with conflicting results. Materials and Methods: Twenty patients (mean age 55.5 +- 14.0 years) after previous repeated administrations of gadoxetate disodium (mean 2.6 +- 1.5) for liver diagnostic process were included. All patients had normal renal and liver functions, an intact blood-brain barrier, and did not receive any other GBCA. They underwent 26 brain magnetic resonance imaging (MRI) with T1WI axial scans for signal intensity (SI) evaluation. The SI changes were measured in globus pallidus (GP), dentate nucleus (DN), pons (Po), and thalamus (Th) and SI ratios (DN/Po, GP/Po, GP/Th, Th/Po) were calculated. The control group consisted of 10 healthy volunteers (mean age 54.8 +- 12.1 years) with no prior GBCA applications. Statistical Analysis: Robust linear regression was used to test the effect of number of applications on the SI ratios. Results: The significant effect of number of gadoxetate previous applications on DN/Po SI ratio was found. On an average, the DN/Po ratio increased by 0.36 percentage points [P = 0.042, 95% CI (0.03, 0.69)]. Other SI ratios were not significantly affected. Conclusions: Repeated administrations of hepatospecific gadoxetate disodium leads to a statistically significant increase in the SI values in DN in patients with normal renal and liver functions, and with an intact blood-brain barrier, probably due to gadolinium deposition.

  • Název v anglickém jazyce

    Gadoxetate disodium, a modern hepatospecific MRI contrast agent: Indirect signs for gadolinium deposition in the brain structures with signal intensity increase after intravenous application

  • Popis výsledku anglicky

    Background: Gadolinium brain deposits after intravenous application of gadolinium-based contrast agents (GBCA) have been recently reported. Aim: We focused selectively on gadoxetate disodium, a hepatospecific linear GBCA. There are currently only a few studies in peer-reviewed literature focused selectively on gadoxetate disodium with conflicting results. Materials and Methods: Twenty patients (mean age 55.5 +- 14.0 years) after previous repeated administrations of gadoxetate disodium (mean 2.6 +- 1.5) for liver diagnostic process were included. All patients had normal renal and liver functions, an intact blood-brain barrier, and did not receive any other GBCA. They underwent 26 brain magnetic resonance imaging (MRI) with T1WI axial scans for signal intensity (SI) evaluation. The SI changes were measured in globus pallidus (GP), dentate nucleus (DN), pons (Po), and thalamus (Th) and SI ratios (DN/Po, GP/Po, GP/Th, Th/Po) were calculated. The control group consisted of 10 healthy volunteers (mean age 54.8 +- 12.1 years) with no prior GBCA applications. Statistical Analysis: Robust linear regression was used to test the effect of number of applications on the SI ratios. Results: The significant effect of number of gadoxetate previous applications on DN/Po SI ratio was found. On an average, the DN/Po ratio increased by 0.36 percentage points [P = 0.042, 95% CI (0.03, 0.69)]. Other SI ratios were not significantly affected. Conclusions: Repeated administrations of hepatospecific gadoxetate disodium leads to a statistically significant increase in the SI values in DN in patients with normal renal and liver functions, and with an intact blood-brain barrier, probably due to gadolinium deposition.

Klasifikace

  • Druh

    J<sub>imp</sub> - Článek v periodiku v databázi Web of Science

  • CEP obor

  • OECD FORD obor

    30224 - Radiology, nuclear medicine and medical imaging

Návaznosti výsledku

  • Projekt

  • Návaznosti

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Ostatní

  • Rok uplatnění

    2018

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název periodika

    Neurology India

  • ISSN

    0028-3886

  • e-ISSN

  • Svazek periodika

    66

  • Číslo periodika v rámci svazku

    6

  • Stát vydavatele periodika

    IN - Indická republika

  • Počet stran výsledku

    5

  • Strana od-do

    1771-1775

  • Kód UT WoS článku

    000452798000042

  • EID výsledku v databázi Scopus